CryoStem Rockets on FDA Nod

By: Dylan Sikes – AllPennyStocks.com News

Wednesday, September 18, 2019

More revolutionary news on the health-care front: Eatontown, New Jersey-based American CryoStem Corporation (OTC:CRYO) saw its stock shoot through the roof Wednesday, on word of its application to the U.S. Food and Drug Administration (FDA).

The company, a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, announced today that it has submitted its first Investigational New Drug Application for its ATCell™ product to the FDA.

The federal body’s acceptance for review of CryoStem’s IND application is a “significant milestone” for the company and represents a meaningful step forward in the treatment of patients suffering from Post Concussion Syndrome. It also aids in the advancement of Regenerative Medicine. We are now one step closer to obtaining approval to treat patients with a cellular therapy derived from the patient’s own adipose tissue.

CRYO’s Phase I Clinical Trial, upon FDA approval, will investigate ATCell™ to provide assessments of the safety and tolerability, and to collect clinical data regarding the alleviation of symptoms associated with Post-Concussion Syndrome.

Stock prices were healthy, though, climbing five cents, or 11.6%, to 48 cents, on volume of 46,000

Copyright © 2019 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon